Abstract
Background: Benign prostatic hyperplasia and prostate cancer are androgen-dependent diseases, and dihydrotestosterone (DHT), a 5α-reduced metabolite of testosterone (T), has been implicated as a causative factor in the progression of these diseases. The 5α-reductase enzyme (5α-R) converts T to DHT, which is responsible for increasing cell proliferation, and hence inhibition of this enzyme could lead to potential treatments for these afflictions.
Objective: This study focused on evaluating the biological activity of three series of pregnenolone derivatives as inhibitors of 5α-R and as antiandrogens on androgen-dependent glands.
Methods: To determine the biological activity of these compounds, we evaluated the effect of each one on suppressing the activity of both types of isozymes of 5α-R (1 and 2) by 50% (IC50). Using animal studies, we assessed the effect of these derivatives on the weight of the prostate, seminal vesicles, and diameter of the flank organs of castrated hamsters previously dosed with 1 mg/Kg T.
Results: In vitro experiments showed that derivatives 1f, 2b, and 3d were very effective inhibitors of the activity of 5α-R2, showing IC50 values of 21.8, 20, and 15 nM, respectively. Derivatives 2b and 3b showed a lower inhibition effect on 5α-R1.
The data also indicated that derivatives 2b, 1f, 3b, and 3d were very active in reducing prostate weight in the hamster model of benign prostatic hyperplasia.
Discussion: Pharmacological experiments showed that pregnenolone derivatives possess an antiandrogenic effect because of the inhibition of DHT production in androgen-dependent glands.
Conclusion: The pregnenolone derivatives studied suppressed type 2 5α-reductase activity and because of this, the weight and dimension of androgen-dependent organs were decreased.
Keywords: Electronegativity effect, flank organ test, pregnenolone derivatives, prostate, seminal vesicles, specificity by 5α- reductase 2, structure-activity improvement, type 2 5α-reductase.
Graphical Abstract
[http://dx.doi.org/10.1002/pros.20188] [PMID: 15538746]
[http://dx.doi.org/10.1021/bi00427a021] [PMID: 2706240]
[http://dx.doi.org/10.2174/0929867323666160210125642] [PMID: 26861003]
[http://dx.doi.org/10.1016/j.steroids.2010.02.005] [PMID: 20170668]
[http://dx.doi.org/10.1021/bi00463a025] [PMID: 2140700]
[http://dx.doi.org/10.1146/annurev.bi.63.070194.000325] [PMID: 7979239]
[PMID: 17986282]
[http://dx.doi.org/10.1016/j.jsbmb.2008.04.008] [PMID: 18556192]
[PMID: 4384673]
[http://dx.doi.org/10.1016/j.bmc.2017.01.018] [PMID: 28174065]
[http://dx.doi.org/10.1248/cpb.50.15] [PMID: 11824579]
[http://dx.doi.org/10.1248/cpb.50.1447] [PMID: 12419908]
[http://dx.doi.org/10.2174/1389557033488196] [PMID: 12570838]
[http://dx.doi.org/10.1248/cpb.52.535] [PMID: 15133203]
[http://dx.doi.org/10.1016/j.steroids.2004.11.008] [PMID: 15763601]
[http://dx.doi.org/10.1016/j.jsbmb.2008.06.014] [PMID: 18644453]
[http://dx.doi.org/10.1016/j.steroids.2010.03.006] [PMID: 20359488]
[http://dx.doi.org/10.1080/14756360600748474] [PMID: 17059168]
[http://dx.doi.org/10.1016/j.ejmech.2015.01.048] [PMID: 25666913]
[http://dx.doi.org/10.1016/j.steroids.2018.01.004] [PMID: 29360536]
[PMID: 9626557]
[http://dx.doi.org/10.1016/j.jsbmb.2011.07.001] [PMID: 21782943]
[http://dx.doi.org/10.1016/0960-0760(96)00050-7] [PMID: 8903421]
[http://dx.doi.org/10.1016/0003-2697(76)90527-3] [PMID: 942051]
[http://dx.doi.org/10.3109/14756366.2015.1070843] [PMID: 26394987]
[http://dx.doi.org/10.1016/j.steroids.2011.05.015] [PMID: 21729714]
[PMID: 12434577]
[http://dx.doi.org/10.1210/endo-96-2-525] [PMID: 163188]
[http://dx.doi.org/10.3923/ajava.2010.202.209]
[http://dx.doi.org/10.1016/j.bmc.2018.06.030] [PMID: 30007568]
[http://dx.doi.org/10.1074/jbc.M010933200] [PMID: 11278790]